Incyte claims double Phase 3 win in vitiligo, will file for approval

April 28, 2026 10:36 AM EDT R&D In­cyte claims dou­ble Phase 3 win in vi­tili­go, will file for ap­proval Elizabeth Cairns Senior biopharma journalist In­cyte in­tends to seek ap­proval of its JAK1 in­hibitor pill in the skin dis­ease non­seg­men­tal vi­tili­go af­ter the drug, povorci­tinib, hit in twin Phase 3 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER